Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740027 | 0.77 | MAPT (0.43) | MAPTTP53GAASMN1; SMN2HASPIN | |
| SCHEMBL6740201 | 0.77 | TP53 (0.44) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL6739243 | 0.75 | CNR2 (0.41) | MAPTTP53GAASMN1; SMN2 | |
| SCHEMBL7078722 | 0.72 | NPY1R (0.38) | — | |
| SCHEMBL6818661 | 0.70 | ALDH1A1 (0.39) | — | |
| SCHEMBL7027847 | 0.69 | — | — | |
| SCHEMBL7034895 | 0.69 | — | — | |
| SCHEMBL7036287 | 0.67 | — | — | |
| SCHEMBL7037439 | 0.67 | — | — | |
| SCHEMBL7029246 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | GILLIGAN PAUL JOSEPH (US) | 2004-02-05 | — | — | US | disclosed |
| US-6579876-B2 | Imidazo(4,5-d)pyridazines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | GILLIGAN PAUL JOSEPH (US) | 2003-03-20 | — | — | US | disclosed |
| US-6521636-B1 | Treatment of psychiatric disorders and neurological diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6365589-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | MAPT 3909/4885TP53 4735/4885GAA 4302/4885 |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | CRH, PCNP, CRHR1 | MAPT 29/4885TP53 3519/4885GAA 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.